Viatris (LTS:0A5V) Debt-to-Equity : 0.81 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Viatris Debt-to-Equity?

Viatris's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1,531 Mil. Viatris's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $14,492 Mil. Viatris's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $19,792 Mil. Viatris's debt to equity for the quarter that ended in Sep. 2024 was 0.81.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Viatris's Debt-to-Equity or its related term are showing as below:

LTS:0A5V' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.65 Med: 1.11 Max: 2.61
Current: 0.81

During the past 13 years, the highest Debt-to-Equity Ratio of Viatris was 2.61. The lowest was 0.65. And the median was 1.11.

LTS:0A5V's Debt-to-Equity is ranked worse than
81.6% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs LTS:0A5V: 0.81

Viatris Debt-to-Equity Historical Data

The historical data trend for Viatris's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Debt-to-Equity Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.09

1.14

0.93

0.90

Viatris Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.89	0.90	0.91	0.89	0.81

Competitive Comparison of Viatris's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Viatris's Debt-to-Equity falls into.

Viatris Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Viatris's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2017.7	+	16353.5)	/	20467.4
	=	0.90

Viatris's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1530.6	+	14491.5)	/	19792.4
	=	0.81

Viatris (LTS:0A5V) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Viatris Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Viatris's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy VIA:Germany VIA:Germany VIA:Germany VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Headlines

No Headlines